The Diabetes
Therapeutics Market was estimated at $ 66.99 billion in 2016, reaching $
186.84 billion by 2023, and is estimated to grow at a 16% CAGR from 2017 to
2023. Important segments, market size and forecasts, and competitive environment.
These insights help market players, investors, stakeholders, and newcomers to
understand the market and gain key market shares and an international presence.
The report provides a complete study of industry
growth drivers, restraints, and opportunities in the global diabetes drug
market. Aging population, increased obesity, urbanization, poor diet,
substandard health in some developing and underdeveloped countries, increased
prevalence of diabetes worldwide, affordable Development of effective
anti-diabetic drugs, growing awareness of people about self-management Diabetes,
government support is driving market growth. However, the side effects of
diabetes drugs and the rigorous drug approval process serve as barriers to
market growth. Conversely, the growing awareness of diabetes treatment in the
developing regions and the untapped market opportunities are expected to
provide an opportunity for industry growth.
The report also provides a detailed analysis of the
diabetes drug market segment. The industry is segmented based on product and
geography. The product segment is divided into injections and oral
antidiabetics (OAD). The injectable segment is divided into insulin,
glucagon-like peptide-1 (GLP-1) receptor agonist / incretin mimetic, and amylin
analog / amylin mimetic. The oral antidiabetic (OAD) segment includes biguanides,
sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors,
dipeptidylpeptidase IV (DPP-4) inhibitors / gliptin, meglitinide, and
sodium-glucose cotransporter-2 ( SGLT2) Inhibitor / glyflozin Geographically,
market analysis is done for regions such as North America, Europe, Asia
Pacific, and LAMEA. In North America, markets across the United States, Canada
and Mexico are analyzed. In Europe, market analysis is conducted in the UK,
Germany, France, Spain, Italy, and other European countries. Asia-Pacific
market research covers China, Japan, India, Australia, South Korea, and other
Asia-Pacific regions. LAMEA's market analysis covers Brazil, Saudi Arabia,
South Africa, and other LAMEAs.
The report offers a comprehensive analysis of the
leading players operating in the diabetes therapeutics market. They include
Biomedical Diagnostics, BioMerieux, Abbott Laboratories, Bio-Rad, Dako,
DiaSorin, Eiken and Fujirebio, Beckman Coulter. They have implemented various
strategies such as partnerships, mergers & acquisitions, expansions, collaborations,
joint ventures, and others to gain a leadership status in the industry.
No comments:
Post a Comment